Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study

Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia A. Koenig, David J. Inwards, Keith Shah, Steven C. Ziesmer, Andrew L. Feldman, Radha Rao, Mamta Gupta, Charles Erlichman, Thomas E. Witzig

Research output: Contribution to journalArticle

129 Scopus citations

Abstract

Background: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphoma. We therefore tested its efficacy and toxicity in combination with rituximab (an antiCD20 antibody) in patients with relapsed or refractory mantle cell lymphoma. Methods: In a phase 2 study, patients (aged ≥18 years) at 35 centres in the USA were given temsirolimus 25 mg/week, and rituximab 375mg/m2 per week for 4 weeks during the first cycle and thereafter a single dose of rituximab every other 28-day cycle. Both drugs were administered intravenously. Responding patients after six cycles could continue treatment for a total of 12 cycles, and were then observed without additional maintenance treatment. The primary endpoint was the proportion of patients with either rituximab-sensitive or rituximab-refractory disease who had at least a partial response. The analyses were done on all patients who were treated. The study was registered with ClinicalTrials.gov, number NCT00109967. Findings: 71 patients with mantle cell lymphoma were enrolled and 69 were assessable and were included in the final analysis. The overall response rate (ORR) was 59% (41 of 69 patients)-13 (19%) patients had complete responses and 28 (41%) had partial responses. The ORR was 63% (30 of 48; 95% CI 47-76) for rituximab-sensitive patients, and 52% (11 of 21; 30-74) for rituximab-refractory patients. The most common treatment-related grade 3 or 4 adverse events in rituximab-sensitive and rituximab-refractory patients were thrombocytopenia (eight [17%] and eight [38%], respectively), neutropenia (ten [21%] and five [24%], respectively), fatigue (eight [17%] and two [10%], respectively), leucopenia (six [13%] and three [14%], respectively), pneumonia (five [10%] and two [10%], respectively), lymphopenia (five [10%] and two [10%], respectively), pneumonitis (four [8%] and none, respectively), oedema (four [8%] and none, respectively), dyspnoea (three [6%] and two [10%], respectively), and hypertriglyceridaemia (three [6%] and two [10%], respectively). Interpretation: mTOR inhibitors in combination with rituximab could have a role in the treatment of patients with relapsed and refractory mantle cell lymphoma. Funding: National Institutes of Health and the Predolin Foundation.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalThe Lancet Oncology
Volume12
Issue number4
DOIs
StatePublished - Apr 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study'. Together they form a unique fingerprint.

  • Cite this

    Ansell, S. M., Tang, H., Kurtin, P. J., Koenig, P. A., Inwards, D. J., Shah, K., Ziesmer, S. C., Feldman, A. L., Rao, R., Gupta, M., Erlichman, C., & Witzig, T. E. (2011). Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. The Lancet Oncology, 12(4), 361-368. https://doi.org/10.1016/S1470-2045(11)70062-6